Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +152 locations
Conditions: Lymphoma
Register for Updates
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282
Completed
RATIONALE: Drugs used in chemotherapy, such as pentostatin, cyclophosphamide, and CAMPATH-1H work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well pentostatin, cyclophospha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +142 locations
Conditions: Leukemia
Register for Updates
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01390584
Terminated
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. Comparing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Stanford Cancer Center, Stanford, California +1 locations
Conditions: Lymphoma
Register for Updates
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
NCT00217425
Completed
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bevacizu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: California Cancer Care, Incorporated - Greenbrae, Greenbrae, California +109 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
NCT00004125
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2023
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +47 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
NCT00049517
Completed
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozoga... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
06/13/2023
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +98 locations
Conditions: Leukemia
Register for Updates
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
NCT02280525
Completed
The goal of this clinical research study is to find the highest tolerable dose of immune cells called natural killer (NK) cells that can be given with chemotherapy to patients with CLL. Researchers want to learn if adding NK cells will be effective in treating the disease. The safety of this will also be studied. NK cells may kill cancer cells that remain in your body after your last chemotherapy treatment. The NK cells will be separated from umbilical cord blood. The device used in the laborat... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
NCT05600686
Recruiting
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and deliver... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Register for Updates
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
NCT01860170
Completed
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2023
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Hematological Malignancy
Register for Updates
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
NCT02285062
Completed
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/22/2023
Locations: Local Institution - 177, Fayetteville, Arkansas +157 locations
Conditions: Lymphoma, Large B-Cell, Diffuse
Register for Updates
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
NCT00656669
Completed
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. This treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading to other parts of the body. This study is being done to test the impact of adding sunitinib as a single-agent (Segment 1), followed by sunitinib plus paclitaxel (Segment 2), followed by doxorubicin and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Breast Cancer
Register for Updates
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768701
Completed
The purpose of this study is to evaluate pembrolizumab therapy in patients with triple-negative breast cancer (TNBC) who have received at least one prior line of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: George Washington University-Medical Faculty Associates, Washington, District of Columbia +4 locations
Conditions: Triple Negative Breast Cancer
Register for Updates